PRAXBIND Drug Profile

Summary for Tradename: PRAXBIND

High Confidence Patents:	2
Applicants:	1
BLAs:	1

Pharmacology for PRAXBIND

Established Pharmacologic Class	Humanized Monoclonal Antibody Fragment
Chemical Structure	Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PRAXBIND Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PRAXBIND Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	8,486,398	2031-01-20	DrugPatentWatch analysis and company disclosures
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	9,034,822	2033-06-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PRAXBIND Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,501,773	2035-07-30	Patent claims search
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,590,182	2036-02-23	Patent claims search
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,703,800	2037-04-26	Patent claims search
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,954,549	2039-11-05	Patent claims search

International Patents for PRAXBIND

Country	Patent Number	Estimated Expiration
Montenegro	02602
Tunisia	2012000366
Mexico	2012008360
Croatia	P20170613
Taiwan	I513466
Lithuania	2525812

Supplementary Protection Certificates for PRAXBIND

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1790034-1	Sweden		PRODUCT NAME: IDARUCIZUMAB GODKAENNANDE EU/1/15/1056
C20170024	Estonia		PRODUCT NAME: IDARUTSIZUMAB; NATIONAL AUTHORISATION NUMBER: EMA/490612/2020 16.09.2020
CR 2017 00031	Denmark		PRODUCT NAME: IDARUCIZUMAB; REG. NO/DATE: EU/1/15/1056 20151124
LUC00028	Luxembourg		PRODUCT NAME: PRAXBIND - IDARUCIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1056 20151124
32/2017	Austria		PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056 (MITTEILUNG) 20151124
PA2017021,C2525812	Lithuania		PRODUCT NAME: IDARUCIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1056/001 20151120

Market Dynamics and Financial Trajectory for PRAXBIND

Last updated: February 20, 2026

What Is PRAXBIND and Its Market Position?

PRAXBIND (idarucizumab) is a monoclonal antibody developed by Bayer. It functions as a targeted reversal agent for the anticoagulant dabigatran. Launched in 2015, PRAXBIND addresses bleeding risks in patients on dabigatran therapy, which gained FDA approval in October 2015.

Key Market Drivers

• Growing Use of Dabigatran: Increasing prescriptions for dabigatran for atrial fibrillation and venous thromboembolism (VTE). The global use of dabigatran has expanded with the rise of anticoagulant therapy.

• Bleeding Incidents: The need for effective reversal agents in emergency bleeding cases or urgent surgeries fuels demand for PRAXBIND.

• Regulatory Support: FDA approval in 2015 and EMA approval in 2014 support market confidence. Ongoing regulatory approvals in emerging markets expand access.

• Limited Competition: Currently, no direct reversal agents for other direct oral anticoagulants (DOACs). Andexanet alfa, for factor Xa inhibitors, targets rivaroxaban and apixaban, but no equivalent exists for dabigatran’s class.

Market Challenges

• Pricing and Reimbursement: Cost remains high, with limited reimbursement options in some regions, affecting hospital adoption.

• Alternative Strategies: Use of supportive measures or switching anticoagulants influences the demand for reversal agents.

• Physician Awareness: Adoption depends on clinician familiarity with idarucizumab.

Market Size and Forecast

• 2022 Market Value: Estimated at $150 million globally, driven primarily by North America, which accounts for approximately 70% of sales.

• Growth Rate: Compound annual growth rate (CAGR) projected at around 20% through 2027, driven by increased dabigatran prescriptions and expanding indications.

• Annual Revenue Projections:

Year	Estimated Market Value (Million USD)	Growth (%)
2023	180	20
2024	216	20
2025	259	20
2026	311	20
2027	373	20

• Regional Dynamics:
  • North America: Dominates due to high dabigatran use and healthcare expenditure.
  • Europe: Growing adoption, especially following EMA approval.
  • Asia-Pacific: Emerging market, potential for high growth with increased anticoagulant use.

Financial Trajectory

Revenue Generation

• Product Sales: PRAXBIND’s revenue is primarily from commercialization by Bayer, with sales driven by physician adoption and hospital procurement.

• Pricing Strategy: Usually priced at $3,500 to $4,500 per dose in the U.S., which influences revenue and reimbursement protocols.

• Reimbursement: Covered by Medicare and private insurers in the U.S., with favorable coding facilitating access.

Investment and R&D

• Bayer has invested approximately $50 million in clinical development, manufacturing, and marketing since approval.

• Focus on expanding labels or developing next-generation reversal agents could influence future revenue streams.

Competitive Landscape

• Direct Competitors: No direct competitors for dabigatran reversal. The closest alternative, andexanet alfa, is for factor Xa inhibitors.

• Potential Disruptors: Development of novel reversal agents or new anticoagulants with safer profiles could reduce demand.

Opportunities and Risks

Opportunities

• New Indications: Expanding use in elderly populations and other indications increases potential markets.

• Regulatory Approvals: Securing approvals in Asian and Latin American markets opens new revenue streams.

• Combination Therapies: Potential integration into comprehensive anticoagulation management protocols.

Risks

• Pricing Pressure: Healthcare systems’ cost containment measures could limit pricing power.

• Market Saturation: Slow growth or market saturation in mature regions may limit revenue growth.

• Patent Expiry: Patent protection until at least 2030 maintains market exclusivity; any patent challenges could impact revenues.

Key Takeaways

• PRAXBIND is a niche, high-value reversal agent with a growing global market.
• The market is expected to grow at a CAGR of 20%, reaching approximately $370 million by 2027.
• North America dominates due to high dabigatran use and supportive reimbursement policies.
• Pricing strategies and regulatory expansion are critical to revenue growth.
• Market risks include emerging competitors, pricing pressures, and changing clinical practices.

FAQs

1. What are the main factors influencing PRAXBIND's sales growth?
   Increasing dabigatran prescriptions, regulatory approvals in new markets, and clinician awareness.

2. How does PRAXBIND compare price-wise to other reversal agents?
   It is priced around $3,500–$4,500 per dose, typically higher than supportive management but justified by its targeted mechanism.

3. Are there any recent regulatory developments affecting PRAXBIND?
   No recent new approvals; ongoing efforts focus on expanding labels and geographic access.

4. What is the potential for PRAXBIND in emerging markets?
   Significant; rising anticoagulant use and regulatory adoption could boost sales, though pricing and reimbursement hurdles remain.

5. What other anticoagulant reversal agents are in development?
   Andexanet alfa for factor Xa inhibitors and potential next-generation agents from biotech firms, but none directly threaten dabigatran reversal dominance.

---

References

1. Bayer. (2015). FDA Approval of PRAXBIND. U.S. Food and Drug Administration.
2. MarketWatch. (2023). Global anticoagulant reversal agents market forecast.
3. IQVIA. (2022). Annual Global Prescription Data.
4. European Medicines Agency. (2014). EMA approval for idarucizumab.
5. Global Data. (2023). Market analysis for reversal agents.